US Wants Another Shot at Gilead’s HIV-Prevention Drug Royalties

The US government, one week after a federal jury voided three of its patents for an HIV-prevention treatment, said it would renew its bid for judgments on a raft of disputed issues and seek a new trial over royalties from Gilead Sciences Inc.’s Truvada and Descovy.

The government intends to file a renewed motion for judgments on direct infringement and on the validity-related issues of anticipation, obviousness, and enablement, according to a joint status report filed Tuesday in the US District Court for the District of Delaware.

The move signals that any fog the case has brought to the research ...